Ovidrel supports management in certain reproductive health scenarios by facilitating a necessary step in the menstrual cycle. The medication assists in conditions where a mature egg needs to be released from the ovary, a process essential for conception. Its primary uses involve aiding women who are undergoing controlled ovarian stimulation as part of Assisted Reproductive Technology (ART), such as in vitro fertilization (IVF).

Additionally, Ovidrel is utilized to promote ovulation in women experiencing infertility due to anovulation (absence of ovulation) or oligo-ovulation (infrequent ovulation) that is not related to primary ovarian failure. This treatment is intended to enable the timely release of the egg, which helps support the overall treatment plan for patients seeking to conceive.

Quick Fact: Support for Ovulation Ovidrel is administered to help trigger the release of a mature egg from the follicle in patients undergoing specific fertility treatments.

Ovidrel is a fertility medicine strictly indicated for use in adult women of reproductive age who are undergoing Assisted Reproductive Technology (ART) or who require ovulation induction for infertility due to anovulation, provided the cause is functional and not due to primary ovarian failure.

Absolute Contraindications (Do Not Use)

The medicine is formally contraindicated by regulatory authorities in women who exhibit the following conditions:

• Pregnancy or known hypersensitivity to choriogonadotropin alfa or its components.
• Primary Ovarian Failure (the ovaries cannot be stimulated to produce eggs).
• Sex-Hormone-Dependent Tumors (e.g., of the ovary, breast, or uterus).
• Uncontrolled Endocrinopathies (e.g., severe thyroid or adrenal dysfunction) or tumors of the pituitary gland.
• Undiagnosed Abnormal Uterine Bleeding or ovarian enlargement/cysts of unknown origin.
• Active Thromboembolic Disorders (blood clotting problems).

Use Limitations and Restrictions

Use is not established in patients with severe renal or hepatic impairment, as safety and efficacy data for these populations are insufficient in regulatory documentation. The use of Ovidrel is not recommended during breastfeeding, and it is not indicated for pediatric or geriatric (post-menopausal) populations.

Interactions with other medicines and products

Official government regulatory bodies have stated that no formal drug-drug interaction studies have been conducted for Choriogonadotropin Alfa (Ovidrel) with other medicinal products. Consequently, regulatory documents do not list specific metabolic, transporter, or pharmacodynamic interactions, and no clinically significant medicinal product interactions have been reported.

Documented Constraints and Absence of Data

1. Procedural Mixing Restriction The Ovidrel solution for injection is subject to a mandatory constraint: it must not be mixed with any other medicinal products in the same syringe or container. This restriction is based on the absence of physical compatibility studies.

2. Interference with Diagnostic Tests Administration of Ovidrel may interfere with laboratory testing, potentially leading to a false positive pregnancy test. Since the medicine is a synthetic analog of Human Chorionic Gonadotropin (hCG), its presence can interfere with the immunological determination of serum or urinary hCG for up to ten days following injection.

3. Food and Substance Status There are no known interactions between Ovidrel and foods or drinks. However, it is officially unknown if the consumption of alcohol will affect the product.

4. Population-Specific Data Gap The pharmacokinetics and safety of Ovidrel have not been established in patients with pre-existing renal or hepatic insufficiency, representing a documented lack of data in these specific populations.

How Ovidrel Works: Pharmacodynamic Mechanism

Ovidrel (choriogonadotropin alfa) is a recombinant drug that acts within the female reproductive system by engaging two distinct mechanistic domains, functionally mimicking the action of endogenous luteinizing hormone (LH).

---

Luteinizing Hormone/Chorionic Gonadotropin Receptor (LHCGR) Agonism

The drug functions as an agonist of the LHCGR, a G-protein-coupled receptor found on ovarian granulosa and theca cells. Binding to this receptor activates the intracellular cAMP-PKA signaling cascade. This pathway modulation is necessary to trigger the final cellular events of oocyte maturation and follicular rupture. This physiological process results in the expulsion of the oocyte from the follicle.

---

Initiation of Luteinization and Progesterone Secretion

Following LHCGR activation, the signaling cascade promotes the structural and functional transformation of the residual follicle into the corpus luteum (luteinization). This transformation is linked to a significant increase in the biosynthesis and subsequent secretion of progesterone. This increase in progesterone contributes to the specific morphological and functional preparation of the endometrium.

How to Use Ovidrel

Ovidrel (choriogonadotropin alfa) is an injectable medicine provided as a pre-filled syringe or pre-filled pen intended for single use. Administration and timing requirements must be followed exactly as prescribed by a healthcare provider to ensure proper use.

---

Official Administration Guidelines

Scope	Instructional Guidelines
Route of Administration	Subcutaneous injection (under the skin).
Dosing Schedule	A single dose of 250 mu g given one time only.
Timing	Must be administered exactly at the date and time specified by the physician.
Preparation	The solution should be checked visually; it must be clear and colorless. No mixing or dilution is required.

---

Procedural Structure

The full procedure centers on a precisely timed, single subcutaneous injection. Patients are instructed to self-administer the medicine into the subcutaneous tissue, typically in the stomach area or the front of the thigh, following their healthcare provider’s training.

Missed-Dose Rules: If the scheduled dose is missed, a patient must immediately contact their doctor or pharmacist for advice; a double dose must never be taken to compensate for a forgotten dose.

Disposal: The pre-filled syringe or pen is strictly for single use. Any unused material and the entire used syringe/needle assembly must be discarded immediately after the single injection into a designated sharps disposal container.

Ovidrel (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin (r-hCG) utilized as a 'trigger shot' in assisted reproductive technologies (ART) and for the induction of ovulation (OI).

Efficacy in Assisted Reproductive Technologies (ART)

Clinical trials have primarily focused on demonstrating the equivalence of r-hCG (Ovidrel) to traditional urinary-derived human chorionic gonadotropin (u-hCG). Data from multicenter, randomized studies confirm that the administration of Ovidrel (typically a 250 µg dose) for final follicular maturation is clinically and statistically comparable to high doses of u-hCG (5,000 IU or 10,000 IU) across key primary endpoints. These endpoints often include the mean number of oocytes retrieved per patient treated, which is a key measure of the drug's effectiveness in triggering the release of mature eggs.

Ovulation Induction (OI) and Clinical Outcomes

In studies involving anovulatory or oligo-ovulatory women undergoing ovulation induction, Ovidrel 250 µg was observed to be non-inferior to u-hCG (5,000 IU) in inducing final follicular maturation and subsequent ovulation. Furthermore, systematic reviews and meta-analyses of randomized controlled trials generally suggest no significant differences in the resulting ongoing pregnancy rates or live birth rates in women treated with r-hCG compared to u-hCG for both ART and OI.

Consistency and Purity

As a recombinant product manufactured through recombinant DNA technology, clinical research notes that Ovidrel offers high purity and consistent batch-to-batch characteristics. This contrasts with u-hCG, which is derived from the urine of pregnant women and may exhibit greater variability in composition.

Common questions about Ovidrel (FAQ)

---

Q: What is the exact volume or concentration of the Ovidrel injection?

A: Official product information for the pre-filled syringe formulation details the concentration. Regulatory documents indicate that the medication is dissolved in a 0.5 mL volume for injection.

---

Q: Will Ovidrel help me get pregnant?

A: Official product information indicates that Ovidrel is used as a fertility medicine to help with the induction of ovulation in infertile women who are eligible for treatment. The medication is used in the final stage of assisted reproductive technology (ART) protocols to trigger the release of mature eggs.

---

Q: What is the exact mechanism that leads to the side effect of Thromboembolism (blood clots)?

A: Official labeling indicates that thromboembolic events (blood clots) are a rare adverse reaction associated with Ovidrel. The documents also note an increased risk in patients with pre-existing risk factors for blood clots, especially when these events are associated with severe Ovarian Hyperstimulation Syndrome (OHSS).

---

Q: Can a nurse or my partner give me the injection instead of me doing it myself?

A: Official drug instructions state that the medicine is administered as a subcutaneous injection. The document notes that a trained healthcare provider or a trained partner may carry out the injection after proper instruction from a physician or clinic.

---

Q: How quickly does Ovidrel work to trigger the eggs?

A: Clinical observations from regulatory data suggest that the final events leading to ovulation are typically timed to occur approximately 36 hours after the single injection is given. The drug’s active substance reaches its maximum concentration in the blood within 12 to 24 hours after the injection.

---

Q: What is the typical monitoring schedule (ultrasounds, bloodwork) after I take the Ovidrel shot?

A: Regulatory documents emphasize the importance of monitoring during ovarian stimulation. They advise that cycles should be followed with regular ultrasound scans and hormone measurements (such as oestradiol) to identify potential risks like Ovarian Hyperstimulation Syndrome (OHSS). Patients who develop OHSS should be clinically followed for at least two weeks.

---

Q: How long after my Ovidrel shot should I wait before taking a home pregnancy test?

A: Official product information notes that because Ovidrel is a synthetic analog of hCG, its presence can interfere with immunological determination. This interference could potentially lead to a false positive pregnancy test for up to ten days following the injection.

How to Store and Dispose of Ovidrel?

Ovidrel (choriogonadotropin alfa) pre-filled syringe requires specific conditions to maintain stability and effectiveness.

Storage Requirements

Condition	Requirement
Primary Temperature	Store in the refrigerator at 36 F to 46 F (2 C to 8 C).
Alternative Temperature	May be stored at room temperature, up to 77 F (25 C), for a maximum of 30 days.
Protection	Keep in the original carton to protect the medication from light. Do not freeze.
Handling	Once stored at room temperature, do not place it back in the refrigerator.

Disposal Instructions

The Ovidrel pre-filled syringe is for single use only. Any unused medicine must be discarded. To prevent harm, the used syringe and needle must be placed immediately into an FDA-cleared, puncture-resistant sharps disposal container. Do not throw the used sharp in household trash or flush unused product down the toilet. Keep all medicine out of the reach of children.